Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

This phase II trial tests whether using genetic testing of tumor tissue to select the optimal treatment regimen works in treating patients with clear cell renal cell (kidney) cancer that has spread to other places in the body (advanced or metastatic). The current Food and Drug Administration (FDA)-approved regimens for advanced kidney cancer fall into two categories. One treatment combination includes two immunotherapy drugs (nivolumab plus ipilimumab), which are delivered by separate intravenous infusions into a vein. The other combination is one immunotherapy drug (nivolumab infusion) plus a

Trial Details

NCT ID
NCT05361720
Phase
PHASE2
Sponsor
Vanderbilt-Ingram Cancer Center
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Cabozantinib
  • Ipilimumab
  • Nivolumab
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Orange, California, United States|33.78779,-117.85311
  • Cleveland, Ohio, United States|41.4995,-81.69541
  • Cleveland, Ohio, United States|41.4995,-81.69541
  • Nashville, Tennessee, United States|36.16589,-86.78444

Key Eligibility Criteria

  • Histological confirmation of RCC with a clear cell component
  • Advanced (not amenable to curative surgery or radiation therapy) or metastatic (American Joint Committee on Cancer \[AJCC\] stage IV) RCC
  • Patient can comprehend and sign the study informed consent form
  • Male or female \>= 18 years of age at the time of informed consent

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →